SRI 31215
Based on 2 publication(s) in Google Scholar
SRI 31215 is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer.
For research use only. We do not sell to patients.
- CAS No.: 1832686-43-7
- Formula: C25H33N5O
- Molecular Weight:419.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) SRI 31215
More
Biological Activity
SRI 31215 has potent activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively[1].
SRI 31215 (10 μM) inhibits the proteolytic activation of pro-HGF[1].
SRI 31215 (10 μM, 30 min) inhibits fibroblast-induced HGF/MET signaling in tumor cells[1].
SRI 31215 (10 μM, 24 h) inhibits fibroblast-induced epithelial mesenchymal transition (EMT) and migration in tumor cells[1].
SRI 31215 (10 μM) overcomes the resistance to EGFR inhibitors mediated by autocrine HGF/MET signaling in colon cancer cells[1].
SRI31215 (10 μM, 72 h) averts fibroblast-mediated resistance to EGFRi-induced apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DU145 cells
-
Concentration:10 μM
-
Incubation Time:30 min
-
Result:Prevented fibroblast-induced MET activation and signaling in tumor cells, but did not prevent MET activation induced by active HGF.
-
Cell Line:DU145 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Did not interfere with HGF-induced migration, but inhibited fibroblast-induced migration of DU145 cells.
Chemical Information
-
CAS No. 1832686-43-7
-
Molecular Weight 419.56
-
Formula C25H33N5O
-
SMILES
N=C(C1=CC=CC(N2CC(C)CN(CC3CCN(CC4=CC=CC=C4)CC3)C2=O)=C1)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Combined Therapy Targeting MET and Pro-HGF Activation Shows Significant Therapeutic Effect Against Liver Metastasis of CRPC. [Abstract]2025 Mar 5;26(5):2308. PMID: 40076928 -
Biomedicines
Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy. [Abstract]2025 Mar 28;13(4):811. PMID: 40299443
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)